Fibroscan by Echosens is available at the office to detect liver fibrosis. Nonalcoholic fatty liver disease affects 37 percent of US adults. Obesity affects 42.4 percent of US adults. All patients with Type 2 diabetes should be screened for liver fibrosis. Patients with 2 or more metabolic coditions should be screened for liver fibrosis. Metabolic conditions include hypertension, dyslipidemia or obesity. Patients who have hepatic steatosis on imaging and elevated liver enzymes should also be screened for liver fibrosis.
The incidence of nonalcoholic steatohepatitis (NASH) is projected to increase by up to 56% over the next 10 years. One quarter of the global population is estimated to have nonalcoholic fatty liver disease (NAFLD). NAFLD is already the fastest growing cause of liver cancer in the USA, France and the UK. Learn how an examination with FibroScan can help.
This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Click on Schedule at the top of the page to schedule an appointment.
-Dr. Joseph K. Sunny, Jr. MD. Gastroenterologist in Miami, Florida.
Self pay accepted.
Currently offering services including evaluation and management of Hepatitis C, fatty liver, abnormal liver enzymes, and celiac disease. By making an appointment, you agree to the "Patient Authorization" below. Click on Schedule at the top of the page to schedule an appointment.